Business development

With a seasoned leadership team with world-class expertise spanning research, clinical development, regulatory, manufacturing and commercial experience in hematologic malignancies, Geron is prepared to deliver on our mission to change lives by changing the course of blood cancer and other hematological conditions.

We are interested in accelerating value creation through strategic partnerships that have the potential to bring complementary programs, products, and capabilities that would synergize with our first-in-class telomerase inhibitor and further address unmet medical needs globally.

To contact our Business Development team, please send us an email.

Scientific collaborators

Starting with our foundational research, Geron has embraced partnerships that advance the scientific understanding of telomere biology, both in the non-clinical and clinical settings. As part of our pipeline expansion, we are exploring imetelstat’s potential in multiple hematologic malignancies, alone and in combination with current standard of care therapies through early-stage trials.

We invite you to discuss possible collaborations with us that could advance the further development of novel telomerase-based therapies or other possible, innovative approaches to the treatment of hematologic malignancies. For all inquiries, please email us.